Tscan therapeutics to host virtual kol event to discuss results from ongoing phase 1 trial of tsc-100 and tsc-101 presented at the 65th ash annual meeting and exposition

Waltham, mass., dec. 04, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the company will host a virtual key opinion leader (kol) event on monday, december 11, at 8:00 a.m. et to discuss highlights from its poster presentation at the 65th american society of hematology (ash) annual meeting and exposition. following the prepared remarks, the call will be opened for a live question and answer session. to submit a question, please reach out to questions@lifesciadvisors.com.
TCRX Ratings Summary
TCRX Quant Ranking